CN115003689A - 具有改变的表面残基的经设计的锚蛋白重复结构域 - Google Patents
具有改变的表面残基的经设计的锚蛋白重复结构域 Download PDFInfo
- Publication number
- CN115003689A CN115003689A CN202080093076.7A CN202080093076A CN115003689A CN 115003689 A CN115003689 A CN 115003689A CN 202080093076 A CN202080093076 A CN 202080093076A CN 115003689 A CN115003689 A CN 115003689A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- seq
- ankyrin repeat
- designed ankyrin
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pregnancy & Childbirth (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19215435 | 2019-12-11 | ||
| EP19215434.2 | 2019-12-11 | ||
| EP19215433.4 | 2019-12-11 | ||
| EP19215436.7 | 2019-12-11 | ||
| EP19215434 | 2019-12-11 | ||
| EP19215435.9 | 2019-12-11 | ||
| EP19215433 | 2019-12-11 | ||
| EP19215436 | 2019-12-11 | ||
| EP20161059.9 | 2020-03-04 | ||
| EP20161059 | 2020-03-04 | ||
| EP20181234.4 | 2020-06-19 | ||
| EP20181234 | 2020-06-19 | ||
| PCT/EP2020/085855 WO2021116462A1 (en) | 2019-12-11 | 2020-12-11 | Designed ankyrin repeat domains with altered surface residues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115003689A true CN115003689A (zh) | 2022-09-02 |
Family
ID=73790118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080093076.7A Pending CN115003689A (zh) | 2019-12-11 | 2020-12-11 | 具有改变的表面残基的经设计的锚蛋白重复结构域 |
| CN202080093012.7A Pending CN114929730A (zh) | 2019-12-11 | 2020-12-11 | 重组肽-mhc复合物结合蛋白及其生成和用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080093012.7A Pending CN114929730A (zh) | 2019-12-11 | 2020-12-11 | 重组肽-mhc复合物结合蛋白及其生成和用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20220106707A1 (https=) |
| EP (2) | EP4073091A1 (https=) |
| JP (2) | JP7794740B2 (https=) |
| KR (2) | KR20220113492A (https=) |
| CN (2) | CN115003689A (https=) |
| AU (2) | AU2020402581A1 (https=) |
| BR (2) | BR112022011456A2 (https=) |
| CA (2) | CA3161326A1 (https=) |
| IL (2) | IL293698A (https=) |
| MX (2) | MX2022007120A (https=) |
| WO (2) | WO2021116469A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL293698A (en) | 2019-12-11 | 2022-08-01 | Molecular Partners Ag | Recombinant peptide-mhc complex binding proteins, their production and use |
| JP2023525518A (ja) | 2020-05-06 | 2023-06-16 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規アンキリンリピート結合タンパク質とその用途 |
| US20240279290A1 (en) | 2020-05-14 | 2024-08-22 | Molecular Partners Ag | Multispecific proteins |
| US11981710B2 (en) | 2020-08-18 | 2024-05-14 | Athebio Ag | N-terminal capping modules of ankyrin repeat domains |
| EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| BR112023018293A2 (pt) | 2021-03-09 | 2023-10-31 | Molecular Partners Ag | Acopladores de célula t multiespecíficos à base de darpin |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| WO2023021050A1 (en) * | 2021-08-17 | 2023-02-23 | Athebio Ag | Variants of ankyrin repeat domains |
| EP4137508A1 (en) * | 2021-08-17 | 2023-02-22 | Athebio AG | Variants of ankyrin repeat domains |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| MX2024007473A (es) * | 2021-12-14 | 2024-09-10 | Cdr Life Ag | Activador del linfocito t dirigido al mhc doble. |
| WO2024028278A1 (en) | 2022-08-01 | 2024-02-08 | Molecular Partners Ag | Charge modified designed repeat domains and their use |
| CA3264474A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT |
| EP4673159A1 (en) | 2023-02-27 | 2026-01-07 | Molecular Partners AG | Darpins for use in reducing renal accumulation of drugs |
| WO2024216244A2 (en) | 2023-04-13 | 2024-10-17 | Regenxbio Inc. | Targeting aav capsids, methods of manufacturing and using same |
| EP4724460A1 (en) * | 2023-06-06 | 2026-04-15 | Molecular Partners AG | Recombinant cd16a binding proteins and their use |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025163144A1 (en) * | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recombinant mesothelin binding proteins and their use |
| WO2025163083A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recobminant dll3 binding proteins and their use |
| DE202024101891U1 (de) | 2024-04-16 | 2025-07-18 | Igus Gmbh | Leitungsführungsvorrichtung für Reinraumanwendungen sowie Halteelement dafür |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| JP2008519590A (ja) | 2004-11-12 | 2008-06-12 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 組換えニューカッスル病ウィルス |
| BRPI0613593A2 (pt) | 2005-07-08 | 2011-01-18 | Univ Zuerich | método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo |
| CN103864893B (zh) | 2007-07-27 | 2017-01-04 | 伊玛提克斯生物技术有限公司 | 免疫疗法的免疫抗原表位 |
| US9365629B2 (en) | 2007-09-24 | 2016-06-14 | University Of Zurich | Designed armadillo repeat proteins |
| BRPI0921469B1 (pt) | 2008-11-03 | 2022-01-18 | Molecular Partners Ag | Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica |
| AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
| PL2643349T3 (pl) | 2010-11-26 | 2020-03-31 | Molecular Partners Ag | Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy |
| EA201391607A1 (ru) * | 2011-04-29 | 2014-04-30 | Янссен Байотек, Инк. | Связывающие il4/il13 белки с повторами и их применение |
| WO2014001442A1 (en) | 2012-06-28 | 2014-01-03 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| WO2014060365A1 (en) | 2012-10-15 | 2014-04-24 | Universität Zürich Prorektorat Mnw | Bispecific her2 ligands for cancer therapy |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| CN105209483B (zh) | 2013-05-31 | 2021-07-27 | 分子组合公司 | 与肝细胞生长因子结合的设计锚蛋白重复蛋白 |
| NZ724320A (en) | 2014-03-14 | 2022-05-27 | Adaptimmune Ltd | Tcr libraries |
| WO2016023898A2 (en) * | 2014-08-11 | 2016-02-18 | Medimmune Limited | Intracellular antigen binding |
| WO2016154246A1 (en) | 2015-03-23 | 2016-09-29 | The Johns Hopkins University | Hla-restricted epitopes encoded by somatically mutated genes |
| KR102427117B1 (ko) | 2015-04-02 | 2022-07-29 | 몰리큘라 파트너스 아게 | 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인 |
| US11827688B2 (en) | 2016-06-02 | 2023-11-28 | Immunocore Limited | Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein |
| CN109790206A (zh) | 2016-09-22 | 2019-05-21 | 分子组合公司 | 重组结合蛋白及其用途 |
| US12065479B2 (en) | 2017-11-16 | 2024-08-20 | The Regents Of The University Of California | Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof |
| JP7611173B2 (ja) | 2019-06-04 | 2025-01-09 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換えfap結合タンパク質及びそれらの使用 |
| CA3138805A1 (en) | 2019-06-04 | 2020-12-10 | Johannes Schilling | Designed ankyrin repeat domain with improved stability |
| WO2020245746A1 (en) | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Multispecific proteins |
| CN114222757A (zh) | 2019-06-04 | 2022-03-22 | 分子伴侣公司 | 重组4-1bb结合蛋白及其用途 |
| WO2021116470A2 (en) | 2019-12-11 | 2021-06-17 | Molecular Partners Ag | Recombinant peptide-mhc complex binding proteins and their generation and use |
| IL293698A (en) * | 2019-12-11 | 2022-08-01 | Molecular Partners Ag | Recombinant peptide-mhc complex binding proteins, their production and use |
| JP2023525518A (ja) * | 2020-05-06 | 2023-06-16 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規アンキリンリピート結合タンパク質とその用途 |
| US20240279290A1 (en) | 2020-05-14 | 2024-08-22 | Molecular Partners Ag | Multispecific proteins |
| US20240279309A1 (en) | 2020-05-14 | 2024-08-22 | Molecular Partners Ag | Recombinant cd40 binding proteins and their use |
-
2020
- 2020-12-11 IL IL293698A patent/IL293698A/en unknown
- 2020-12-11 AU AU2020402581A patent/AU2020402581A1/en active Pending
- 2020-12-11 WO PCT/EP2020/085863 patent/WO2021116469A2/en not_active Ceased
- 2020-12-11 BR BR112022011456A patent/BR112022011456A2/pt not_active Application Discontinuation
- 2020-12-11 MX MX2022007120A patent/MX2022007120A/es unknown
- 2020-12-11 WO PCT/EP2020/085855 patent/WO2021116462A1/en not_active Ceased
- 2020-12-11 BR BR112022011177A patent/BR112022011177A2/pt not_active Application Discontinuation
- 2020-12-11 JP JP2022535443A patent/JP7794740B2/ja active Active
- 2020-12-11 KR KR1020227023764A patent/KR20220113492A/ko not_active Withdrawn
- 2020-12-11 KR KR1020227023763A patent/KR20220113491A/ko not_active Withdrawn
- 2020-12-11 MX MX2022007122A patent/MX2022007122A/es unknown
- 2020-12-11 EP EP20821220.9A patent/EP4073091A1/en active Pending
- 2020-12-11 CA CA3161326A patent/CA3161326A1/en active Pending
- 2020-12-11 JP JP2022535453A patent/JP2023506765A/ja active Pending
- 2020-12-11 CN CN202080093076.7A patent/CN115003689A/zh active Pending
- 2020-12-11 IL IL293704A patent/IL293704A/en unknown
- 2020-12-11 AU AU2020399230A patent/AU2020399230A1/en active Pending
- 2020-12-11 CN CN202080093012.7A patent/CN114929730A/zh active Pending
- 2020-12-11 CA CA3161321A patent/CA3161321A1/en active Pending
- 2020-12-11 EP EP20821221.7A patent/EP4073092A2/en not_active Withdrawn
-
2021
- 2021-08-02 US US17/392,204 patent/US20220106707A1/en not_active Abandoned
- 2021-08-12 US US17/400,471 patent/US11578427B2/en active Active
-
2023
- 2023-01-12 US US18/153,576 patent/US12435445B2/en active Active
- 2023-02-24 US US18/174,086 patent/US20230243070A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3161321A1 (en) | 2021-06-17 |
| AU2020402581A1 (en) | 2022-06-23 |
| EP4073092A2 (en) | 2022-10-19 |
| AU2020399230A1 (en) | 2022-06-23 |
| US20230340698A1 (en) | 2023-10-26 |
| JP7794740B2 (ja) | 2026-01-06 |
| KR20220113491A (ko) | 2022-08-12 |
| WO2021116462A1 (en) | 2021-06-17 |
| CA3161326A1 (en) | 2021-06-17 |
| US12435445B2 (en) | 2025-10-07 |
| AU2020402581A9 (en) | 2022-07-14 |
| MX2022007120A (es) | 2022-09-09 |
| US20230243070A1 (en) | 2023-08-03 |
| IL293704A (en) | 2022-08-01 |
| WO2021116469A3 (en) | 2021-12-02 |
| EP4073091A1 (en) | 2022-10-19 |
| BR112022011456A2 (pt) | 2022-08-23 |
| JP2023506765A (ja) | 2023-02-20 |
| BR112022011177A2 (pt) | 2022-09-27 |
| US11578427B2 (en) | 2023-02-14 |
| KR20220113492A (ko) | 2022-08-12 |
| US20220064234A1 (en) | 2022-03-03 |
| MX2022007122A (es) | 2022-09-09 |
| CN114929730A (zh) | 2022-08-19 |
| WO2021116469A2 (en) | 2021-06-17 |
| JP2023506757A (ja) | 2023-02-20 |
| US20220106707A1 (en) | 2022-04-07 |
| IL293698A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12435445B2 (en) | Designed ankyrin repeat domains with altered surface residues | |
| CN103459415B (zh) | 设计的与血清白蛋白结合的重复蛋白 | |
| EP3004152B1 (en) | Designed ankyrin repeat proteins binding to hepatocyte growth factor | |
| EP2867360B1 (en) | Designed ankyrin repeat proteins binding to platelet-derived growth factor | |
| CN114206908B (zh) | 具有改善的稳定性的经设计的锚蛋白重复结构域 | |
| HK40059771A (en) | Designed repeat proteins binding to serum albumin | |
| HK1213001B (zh) | 与肝细胞生长因子结合的设计锚蛋白重复蛋白 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |